Shock Wave Therapy for Calcific Shoulder Pain: Where It Ranks

Shock wave therapy can improve pain and function in calcific rotator cuff tendinopathy, but it does not currently rank as the leading conservative treatment. A 2025 network meta-analysis placed platelet-rich plasma (PRP) and EDTA-based treatment ahead of extracorporeal shock wave therapy (ESWT) for both pain and shoulder function. The useful lesson is less glamorous than a "best treatment" headline: ESWT outcomes depend heavily on the protocol, especially energy dose, and combinations may outperform a single approach.

That puts ESWT in the category of a reasonable treatment with real evidence—not a universal winner, and not a treatment that can be judged by its name alone.

Why the treatment ranking matters

For rotator cuff calcific tendinopathy, clinicians can choose among shock waves, injections, needling procedures, taping, and sham or placebo care. Most trials compare only two options. A 2025 network meta-analysis by Moggio et al. combined direct and indirect randomized comparisons across this wider field, assessing pain on VAS or NRS scales and function with the Constant–Murley Score.

The review separated ESWT into high energy flux density (EFD; greater than 0.3 mJ/mm²), medium EFD (0.2–0.3 mJ/mm²), and low EFD (less than 0.2 mJ/mm²). That distinction is overdue. Calling every shock-wave protocol "ESWT" is like treating a teaspoon and a tablespoon as the same dose because both contain salt.

All active treatments ranked above placebo or sham. Yet PRP and EDTA-based approaches ranked above ESWT for pain relief and functional improvement. The publication's available results do not provide the numerical SUCRA values or their uncertainty estimates, so the ranking cannot be translated into a precise expected advantage for an individual patient. Still, the direction of the hierarchy is clear: ESWT has support, but it is not automatically the first conservative choice when PRP or EDTA are available and appropriate.

Energy dose may explain why older ESWT studies disagree

Older reviews often pooled protocols with different energy levels, session counts, and impulse numbers. The 2025 network analysis partly corrected that problem by assigning different EFD ranges to separate treatment nodes. It does not prove a specific dose prescription, but it makes a practical point: a low-energy protocol and a high-energy protocol should not be expected to perform identically.

A 2024 systematic review and meta-analysis by Xue et al. pooled randomized evidence across pain, function, range-of-motion, and shoulder-specific scales. It also discussed an earlier meta-analysis that found only slight short-term pain improvement versus sham ESWT and no superiority over sham for function. Those findings should remain in view rather than being erased by newer positive trials.

The disagreement may reflect more than chance. Studies differ in patient diagnosis, comparator, follow-up, energy settings, number of sessions, and outcome measures. Some reports also omit the EFD needed to compare protocols properly. A newer synthesis can improve the evidence base, but it cannot make heterogeneous protocols interchangeable.

Focused, radial, or both?

A three-arm randomized trial by Abo Al-Khair et al. offers one direct answer for people whose main problem is a calcific deposit. Forty-five patients with calcific shoulder tendinopathy were randomized to four weekly sessions of focused ESWT (1,500 impulses), radial ESWT (2,000 impulses), or combined focused-plus-radial treatment; each group had 15 participants.

At one week and three months after treatment, all three groups improved in pain, active range of motion, and Shoulder Disability Questionnaire scores. Ultrasound also showed that the combined-treatment group had greater calcification-size reduction than either single-modality group.

That structural result is clinically relevant because calcification is part of the disease rather than a laboratory curiosity. But it is not a license to declare combined ESWT the settled standard. The trial was small, and the reported information does not include between-group p-values or effect sizes for the calcification comparison. It signals a potentially useful protocol refinement; it does not establish the size or durability of the advantage.

Against deep friction massage, ESWT improved selected outcomes

ESWT also beat an active manual-therapy comparator in a small but informative trial. In a 2025 randomized trial by Karimiahmadabadi et al., 32 non-professional athletes with supraspinatus tendinitis received either focused ESWT plus exercise or deep friction massage plus exercise. Outcomes were measured at baseline, after 12 sessions, and one week later.

The ESWT group had better pain results than the massage group (between-group p=0.024; effect size −0.84). It also had higher pressure-pain thresholds at the supraspinatus (p=0.0001; effect size 1.65) and deltoid (p<0.0001; effect size 2.61), plus better shoulder-abduction range of motion (p=0.001; effect size 1.31). These are large standardized effects, particularly for a conservative musculoskeletal treatment.

The benefits were not universal. Groups did not differ significantly in external rotation (p=0.2), supraspinatus strength (p=0.42), or quality of life (p=0.97). The study also enrolled supraspinatus tendinitis rather than calcific tendinopathy, so it cannot directly settle treatment choices for calcific deposits. Neither participants nor therapists could realistically be blinded to shock waves versus massage, which leaves room for expectation and performance effects. With only 32 participants, the large estimates need replication.

Combination treatment is promising, but the endpoints differ

Several trials ask a more useful clinical question than "Does ESWT work?": does it add something to an injectable treatment?

In a double-blinded randomized study by Ko et al., patients with rotator cuff lesions without a complete tear received three hyaluronic acid injections with either two sham ESWT sessions, one ESWT and one sham session, or two ESWT sessions. Pain, Constant–Murley Score, range of motion, and abduction strength were assessed through 12 months, with shoulder MRI before treatment and at 12 months. All groups improved over time, and the study reported a dose-dependent benefit from adding ESWT to hyaluronic acid. This is stronger design evidence than an unblinded comparison, although the available results do not provide enough numerical detail to quantify the added benefit here.

A separate randomized open-label trial by Pellegrino et al. compared ultrasound-guided peritendinous hyaluronic acid plus ESWT with ESWT alone in 40 adults with rotator cuff tendinopathy. The combination produced greater pain reduction and functional improvement at 30 and 60 days. Open-label design makes subjective outcomes more vulnerable to expectations, and two months does not answer whether the difference lasts.

For partial rotator cuff tears, a 2024 randomized comparative study by Kuo et al. compared PRP alone with PRP plus ESWT over six months. Both groups improved in pain, Constant–Murley Score, and several motion measures. Adding ESWT improved forward flexion at one month (p=0.033), abduction at one month (p=0.015), and total shoulder range of motion at six months (p<0.001). These findings concern partial tears, not calcific tendinopathy, so they should not be folded into the treatment ranking for calcific disease.

What mechanism studies and postoperative trials can—and cannot—tell us

A 2025 prospective case-control study by Chou et al. measured clinical, ultrasound, and molecular changes after ESWT for calcific shoulder tendinitis. Biomarkers can help generate plausible biological explanations, but they do not prove that a molecular change caused symptom relief or deposit resorption.

ESWT has also been tested after surgery. In a 2023 randomized trial by Shao et al., 38 people began radial ESWT three months after rotator cuff repair while both groups completed five weeks of advanced rehabilitation. The ESWT group received 2,000 pulses weekly for five weeks. The study reported less pain and better proximal tendon healing than rehabilitation alone. Postoperative rehabilitation is a different clinical setting from treating an intact, calcific tendon, so it broadens the research agenda rather than supporting self-referral for every painful shoulder.

The practical verdict

ESWT deserves consideration for calcific rotator cuff tendinopathy, especially when a clinic can specify the energy flux density, number of sessions, and whether it uses focused or radial waves. The best comparative evidence ranks PRP and EDTA-based options higher for pain and function, while combined focused-plus-radial ESWT showed greater calcification resorption than either format alone in one small trial.

Ask the clinician what diagnosis they are treating, what EFD they plan to use, and what the realistic alternative is: PRP, EDTA-based treatment, needle aspiration, rehabilitation, or watchful waiting. Women make up a substantial share of the calcific-tendinopathy population, yet the shoulder trials discussed here did not report sex-stratified results. A 2025 cohort study in runners found that sex and hormonal factors were associated with ESWT outcomes in Achilles and hamstring tendinopathy; that result cannot be assumed to apply to shoulders, but it identifies a gap worth fixing.

The evidence supports a measured conclusion: ESWT can help, protocol details matter, and combination treatment warrants longer, adequately powered trials before anyone calls it the default answer.